KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Interest Expenses (2017 - 2025)

Aquestive Therapeutics has reported Interest Expenses over the past 9 years, most recently at $2.8 million for Q4 2025.

  • Quarterly results put Interest Expenses at $2.8 million for Q4 2025, changed 0.04% from a year ago — trailing twelve months through Dec 2025 was $11.1 million (changed 0.02% YoY), and the annual figure for FY2025 was $11.1 million, changed 0.02%.
  • Interest Expenses for Q4 2025 was $2.8 million at Aquestive Therapeutics, roughly flat from $2.8 million in the prior quarter.
  • Over the last five years, Interest Expenses for AQST hit a ceiling of $2.8 million in Q3 2021 and a floor of $1.3 million in Q3 2023.
  • Median Interest Expenses over the past 5 years was $2.8 million (2021), compared with a mean of $2.3 million.
  • Biggest five-year swings in Interest Expenses: crashed 41.4% in 2022 and later soared 121.34% in 2024.
  • Aquestive Therapeutics' Interest Expenses stood at $1.7 million in 2021, then fell by 5.39% to $1.6 million in 2022, then surged by 37.76% to $2.3 million in 2023, then increased by 22.26% to $2.8 million in 2024, then dropped by 0.04% to $2.8 million in 2025.
  • The last three reported values for Interest Expenses were $2.8 million (Q4 2025), $2.8 million (Q3 2025), and $2.8 million (Q2 2025) per Business Quant data.